These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 27576370

  • 1. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
    Inati A, Kahale M, Sbeiti N, Cappellini MD, Taher AT, Koussa S, Nasr TA, Musallam KM, Abbas HA, Porter JB.
    Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
    Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock CA, Traficante R, Gervasio OL, Bowden DK.
    Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786
    [Abstract] [Full Text] [Related]

  • 6. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
    Pennell DJ, Porter JB, Piga A, Lai YR, El-Beshlawy A, Elalfy M, Yesilipek A, Kilinç Y, Habr D, Musallam KM, Shen J, Aydinok Y, CORDELIA study investigators.
    Am J Hematol; 2015 Feb; 90(2):91-6. PubMed ID: 25345697
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF.
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [Abstract] [Full Text] [Related]

  • 9. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.
    Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, Malfertheiner P, McLaren GD, Niederau C, Piperno A, Powell LW, Russo MW, Stoelzel U, Stremmel W, Griffel L, Lynch N, Zhang Y, Pietrangelo A.
    Hepatology; 2010 Nov; 52(5):1671-779. PubMed ID: 20814896
    [Abstract] [Full Text] [Related]

  • 10. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
    Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y.
    Blood; 2011 Jul 28; 118(4):884-93. PubMed ID: 21628399
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
    Merchant R, Ahmed J, Krishnan P, Jankharia B.
    Indian Pediatr; 2012 Apr 28; 49(4):281-5. PubMed ID: 21992861
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F.
    Pediatr Hematol Oncol; 2014 Feb 28; 31(1):76-86. PubMed ID: 24383712
    [Abstract] [Full Text] [Related]

  • 14. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
    Porter JB, Elalfy M, Taher A, Aydinok Y, Lee SH, Sutcharitchan P, El-Ali A, Han J, El-Beshlawy A.
    Eur J Haematol; 2017 Mar 28; 98(3):280-288. PubMed ID: 27859648
    [Abstract] [Full Text] [Related]

  • 15. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
    Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A.
    Haematologica; 2011 Jan 28; 96(1):48-54. PubMed ID: 21071497
    [Abstract] [Full Text] [Related]

  • 16. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.
    Busca A, Falda M, Manzini P, D'Antico S, Valfrè A, Locatelli F, Calabrese R, Chiappella A, D'Ardia S, Longo F, Piga A.
    Biol Blood Marrow Transplant; 2010 Jan 28; 16(1):115-22. PubMed ID: 19766730
    [Abstract] [Full Text] [Related]

  • 17. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY, Li Q, Chen JJ, Chen GF, Li CG.
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul 28; 13(7):531-4. PubMed ID: 21752315
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
    Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A.
    Eur J Haematol; 2009 Jun 28; 82(6):458-65. PubMed ID: 19187278
    [Abstract] [Full Text] [Related]

  • 19. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep 28; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 20. The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.
    Chang HH, Lu MY, Peng SS, Yang YL, Lin DT, Jou ST, Lin KH.
    Ann Hematol; 2015 Dec 28; 94(12):1945-52. PubMed ID: 26404899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.